Pre-surgery treatment for liver cancer at high risk of return
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have not had any previous treatment for your liver cancer (like surgery, chemo, or targeted therapy).
- Your liver is still working fairly well (Child-Pugh score 7 or less).
- You are able to take care of most daily activities on your own (ECOG 0 or 1).
- Your liver tumor can be removed by surgery, but it is at high risk of coming back (for example, a single tumor 5 cm or larger, or multiple tumors, or the tumor has spread into nearby blood vessels but not to other organs).
- A special computer model using your tumor tissue, scans, and genetic data predicts that you will benefit from a treatment plan of HAIC (hepatic artery infusion chemotherapy) combined with lenvatinib (a targeted pill) and a PD-1 inhibitor (immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of targeted therapy and immunotherapy before surgery can shrink liver tumors and improve outcomes in people with intermediate-stage liver cancer. The study uses a special computer model to see if you might benefit from this approach.
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
This study tests a new approach: giving two immunotherapy drugs (sintilimab and ipilimumab) along with treatments that block blood flow to the tumor (TACE or ablation) before surgery for liver cancer that is at high risk of coming back. The goal is to see if this combination can shrink the tumor and reduce the chance of recurrence after surgery.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.